HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

CanSino Biologics (688185.CH/6185.HK) - Time for Corner Overtaking?

Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?

Pre-IPO YishengBio Co., Ltd  - Here Are the Concerns Despite Solid Market Potential

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Beijing Advaccine Biotechnology / Equity Capital Markets

<p>No one could have imagined that the world of 2020 would be radically changed by the COVID-19. The invisible virus is so fierce, and humans, surrounded by high technology, are so fragile that they have to rely on vaccines to return to normal life. With hundreds of COVID-19 vaccine R&amp;D teams around the world working hard to develop vaccines, it is not known who would be the terminator of COVID-19. <a href="https://www.smartkarma.com/entities/beijing-advaccine-biotechnology-co-ltd" target="_blank" data-smartkarma-citation="entities:33147:1" rel="noopener">Beijing Advaccine Biotechnology (BAB HK)</a> is one of them. On April 26, Advaccine, an innovative vaccine company, filed an application to list on the main board of the Hong Kong Stock Exchange, and the core product is a vaccine candidate for COVID-19. So could Advaccine become the terminator? This insights mainly analyzed the vaccine candidates in the pipeline.</p>

No one could have imagined that the world of 2020 would be radically changed by the COVID-19. The invisible virus is so fierce, and humans, surrounded by high technology, are so fragile that they have to rely on vaccines to return to normal life. With hundreds of COVID-19 vaccine R&amp;D teams around the world working hard to develop vaccines, it is not known who would be the terminator of COVID-19. Beijing Advaccine Biotechnology (BAB HK) is one of them. On April 26, Advaccine, an innovative vaccine company, filed an application to list on the main board of the Hong Kong Stock Exchange, and the core product is a vaccine candidate for COVID-19. So could Advaccine become the terminator? This insights mainly analyzed the vaccine candidates in the pipeline.

Pre-IPO Beijing Advaccine Biotechnology - Would the “new Force” Become the Terminator of COVID-19?